Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 48

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 48
---
 favorable alternative acquisition proposal, and provide that, in specified circumstances, we would be required to pay a termination fee to Kaken of $3.5 million. |

| • |     | Aadi will incur significant expenses in connection with the Divestiture, regardless of whether the Divestiture is 
 completed.                                                                                                        |

| • |     | Our executive officers and directors may have interests in the Divestiture other than, or in addition to, the 
 interests of our stockholders generally.                                                                      |

| • |     | Lawsuits may be filed against Aadi challenging the Divestiture and an adverse ruling in any such lawsuit may 
 prevent the Divestiture from being completed at all or from being completed within the expected time frame.  |

Risks Related to the PIPE Financing

| • |     | Our stockholders will experience significant dilution as a result of the PIPE Financing if the PIPE Financing                                                                                         
 Proposal is approved at the Special Meeting, as the number of shares we have agreed to sell in the PIPE Financing is significant in relation to the number of outstanding shares of our common stock. |

| • |     | If the PIPE Financing Proposal is approved and the PIPE Offering is completed, a substantial number of shares of                                                                                                            
 common stock will be restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well. |

| • |     | We may become obligated to pay liquidated damages if we fail to file, obtain effectiveness and maintain                                                                                    
 effectiveness of the resale registration statement in accordance with the terms of the Subscription Agreement and the form of Registration Rights Agreement related to the PIPE Financing. |

| • |     | Some Aadi directors, executive officers and principal stockholders have interests in the PIPE Financing that are            
 different from yours and that may influence them to support or approve the PIPE Financing without regard to your interests. |

- 32 -

Risks Related to the License Agreement and the ADC Programs

| • |     | Following the Divestment, we will not have any approved products and our pipeline will comprise solely of                                                                                                                                                 
 preclinical assets. The ADC Programs are early in development. Going forward, our business will depend on our ability to advance our current and future product candidates through preclinical studies and clinical trials and obtain regulatory approval 
 of our product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.                                                                                                                               |

| • |     | Through the